Comprehensive comparison of monotherapies for psychiatric hospitalization risk in bipolar disorders.
Anastasiya NestsiarovichAurélien J MazurieNathaniel G HurwitzBerit KernerStuart J NelsonAnnette S CrisantiMauricio TohenRonald L KrallDouglas J PerkinsChristophe Gerard LambertPublished in: Bipolar disorders (2018)
This largest reported retrospective observational study on bipolar disorders pharmacotherapy to date demonstrates that the majority of patients end monotherapy within 2 months after treatment start. The risk of psychiatric hospitalization varied almost two-fold across individual medications. The data add to the evidence favoring lithium and mood stabilizer use in short-term bipolar disorder management. The findings that the dopaminergic drugs aripiprazole and bupropion had better outcomes than other members of their respective classes and that antidepressant outcomes may vary by baseline mood polarity merit further investigation.
Keyphrases
- bipolar disorder
- major depressive disorder
- end stage renal disease
- mental health
- ejection fraction
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- cross sectional
- big data
- clinical trial
- depressive symptoms
- open label
- metabolic syndrome
- weight loss
- deep learning
- patient reported
- clinical evaluation